Compare RITM & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RITM | LEGN |
|---|---|---|
| Founded | 2011 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.5B | 5.9B |
| IPO Year | N/A | 2020 |
| Metric | RITM | LEGN |
|---|---|---|
| Price | $10.70 | $18.54 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 8 | 14 |
| Target Price | $14.56 | ★ $63.46 |
| AVG Volume (30 Days) | ★ 10.8M | 3.1M |
| Earning Date | 02-03-2026 | 03-10-2026 |
| Dividend Yield | ★ 9.37% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.04 | N/A |
| Revenue | ★ $3,136,826,000.00 | $909,045,000.00 |
| Revenue This Year | N/A | $67.56 |
| Revenue Next Year | $4.04 | $45.77 |
| P/E Ratio | $10.26 | ★ N/A |
| Revenue Growth | N/A | ★ 74.75 |
| 52 Week Low | $9.13 | $16.24 |
| 52 Week High | $12.74 | $45.30 |
| Indicator | RITM | LEGN |
|---|---|---|
| Relative Strength Index (RSI) | 37.68 | 42.75 |
| Support Level | $10.53 | $16.82 |
| Resistance Level | $10.87 | $17.38 |
| Average True Range (ATR) | 0.32 | 0.78 |
| MACD | -0.11 | 0.17 |
| Stochastic Oscillator | 11.76 | 61.55 |
Rithm Capital Corp operates as a real estate investment trust that provides capital and services to the real estate and financial services industries. The company aims to generate attractive risk-adjusted returns in all interest-rate environments through a complementary portfolio of investments and operating businesses. Its investment portfolio is composed of mortgage servicing-related assets (full and excess MSRs and servicer advances), residential securities (and associated call rights) loans (including single-family rental), and consumer loans. Its operating segments are Origination and Servicing; Investment Portfolio; Residential Transitional Lending; and Asset Management.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.